HOME >> BIOLOGY >> NEWS
GlaxoSmithKline Drug Discovery and Development Research Grant Program 2004

GlaxoSmithKline (GSK) is pleased to announce a call for applications for its 2004 Drug Discovery and Development Research Grant Program. GSK will award $250,000 in grants for innovative HIV/AIDS drug research in recognition of the need to produce new alternatives and hope in the fight against the HIV/AIDS pandemic. Since the inception of the program in 2001, GSK has awarded $1.25 million and honored 14 researchers for their groundbreaking work toward new pharmaceutical strategies to combat the HIV virus.

Applications are now being solicited for 2004 research grants and must be submitted by July 31. For detailed information about the GSK Drug Discovery and Development Research Grant Program, as well as an application, please call 1-888-527-6935 or visit www.dddresearchgrant.com.

The one-time research grants range from $25,000 to $150,000 and are intended to further the development of inventive treatments for HIV/AIDS, including:

  • therapies aimed at treating infection,
  • prophylactic vaccines, or
  • microbicides designed to prevent transmission of the virus.

"As we enter the fourth year of the program, it's rewarding to witness the progress that the first grant recipients have made. The grants have enabled researchers to improve testing processes, submit research for publication, experiment with new hypotheses and strive to develop medications and vaccines for patients worldwide," said Doug Manion, M.D., vice president of clinical development and medical affairs for GSK. "We are pleased to help researchers in their quest to unlock the mysteries of HIV."

The research grant carries no obligation to the recipient's organization for licensure, patenting or transfer of confidential information, although GSK may discuss the possibility of future collaboration with some applicants.

An Expert Review Board composed of acknowledged leaders in the field of HIV/AIDS w
'"/>

Contact: Teresa Luepke
tluepke@pcipr.com
312-558-1770
Public Communications Inc.
30-Apr-2004


Page: 1 2 3

Related biology news :

1. Results of pivotal study for GlaxoSmithKlines Valtrex published in New England Journal of Medicine
2. July 31 deadline approaching to apply for $500,000 in research grants from GlaxoSmithKline
3. Discovery of new shrimp species adds to unique family
4. Discovery of tiny microbes in ancient Greenland glacier may define limits for life on Earth
5. Discovery in parasite movement may offer insights into malaria
6. Scientists find second way to kill cancer cells: Discovery opens possibilities for new therapies
7. Discovery helps explain how cells package DNA
8. Discovery offers clues to origin of life
9. Discovery could improve anemia treatment in patients
10. Discovery could lead to better treatment for cryptosporidum infections
11. Discovery of brain disorder gene paves way for genetic test

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: